Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "motor neuron disease" Clear all
Not yet recruiting Early Phase 1 Interventional

Collagenase Injection for Spasticity Management

NCT07693569
View directory record Official record
Conditions
Spasticity
Interventions
XIAFLEX Collagenase injection
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 24, 2026, 12:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)

NCT02000713
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MRI, Clinical Exam
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
ORT247, Placebo
Drug
Lead sponsor
Orthogonal Neuroscience Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Escitalopram (Lexapro) for Depression MS or ALS

NCT00965497
View directory record Official record
Conditions
Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Interventions
escitalopram
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT02460679
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
EPI-589
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
21 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Effects of Cholinergic Augmentation on Measures of Balance and Gait

NCT02206620
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Donepezil
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease

NCT07625605
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
Interventions
The MIND diet
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
30 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Elizabethton, Tennessee • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 24, 2026, 12:59 AM EDT
Terminated Phase 1 Interventional Results available

Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy

NCT03381729
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Onasemnogene Abeparvovec-xioi
Biological
Lead sponsor
Novartis Gene Therapies
Industry
Eligibility
6 Months to 60 Months
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Results available

Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis

NCT03241784
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Autologous T-regulatory lymphocytes, Interleukin-2
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 24, 2026, 12:59 AM EDT
Completed No phase listed Observational

Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restoration

NCT05219487
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Risdiplam
Drug
Lead sponsor
Bakri Elsheikh
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 24, 2026, 12:59 AM EDT
Completed No phase listed Observational Results available

A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)

NCT01047306
View directory record Official record
Conditions
Sanfilippo Syndrome Type A
Interventions
assessment
Other
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics

NCT04578912
View directory record Official record
Conditions
Tic Disorders, Tics, Tic, Motor, Tic Disorder, Childhood, Tourette Syndrome, Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions
Comprehensive Behavioral Intervention for Tics (CBIT), Repetitive Transcranial Magnetic Stimulation (rTMS), Continuous Theta Burst Stimulation (cTBS)
Behavioral · Device
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 24, 2026, 12:59 AM EDT
Terminated Phase 3 Interventional

Continuation Study for Latozinemab

NCT06111014
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
Latozinemab
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 24, 2026, 12:59 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Brain State-dependent PCMS in Chronic Stroke

NCT04830163
View directory record Official record
Conditions
Stroke
Interventions
Brain state-dependent paired corticomotoneuronal stimulation (PCMS)
Combination Product
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Jul 24, 2026, 12:59 AM EDT
Recruiting No phase listed Observational

Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth

NCT07491484
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Amyotrophic Lateral Sclerosis Assessment Questionnaire-40
Other
Lead sponsor
TidalHealth, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 24, 2026, 12:59 AM EDT
Not listed Early Phase 1 Interventional

Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury

NCT06274021
View directory record Official record
Conditions
Spinal Cord Injuries, Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic
Interventions
Transcutaneous spinal stimulation at 100 Hz, Transcutaneous spinal stimulation at 50 Hz, Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen, Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine, Sham transcutaneous spinal stimulation
Device · Combination Product
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 24, 2026, 12:59 AM EDT
Terminated No phase listed Observational

Long-term Surveillance of the MedStream Programmable Infusion System

NCT01712087
View directory record Official record
Conditions
Spasticity
Interventions
MedStream Programmable Infusion System
Device
Lead sponsor
Codman & Shurtleff
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Worcester, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

NCT01536249
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Cimetidine plus Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Jul 24, 2026, 12:59 AM EDT
Recruiting Phase 2 Interventional

Study of COYA 302 for the Treatment of ALS

NCT07161999
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
COYA 302, Placebo
Drug
Lead sponsor
Coya Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Structural and Functional Brain Connectivity Changes in ALS (CoALS-II)

NCT05404867
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
fMRI
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jul 24, 2026, 12:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)

NCT01166022
View directory record Official record
Conditions
Spinal Muscular Atrophy, Neuromuscular Disease
Interventions
Exercise
Other
Lead sponsor
Columbia University
Other
Eligibility
8 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Jul 24, 2026, 12:59 AM EDT
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jul 24, 2026, 12:59 AM EDT
Not listed Not applicable Interventional

EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis

NCT06169696
View directory record Official record
Conditions
Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis, Spinal Cord Injuries, Cervical Spinal Cord Injury, Tetraplegic; Paralysis, Quadriplegia/Tetraplegia
Interventions
Intervention/Treatment
Device
Lead sponsor
Synaptrix Labs Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Jul 24, 2026, 12:59 AM EDT